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TMB-8 is widely regarded as an ‘intrac&ular calcium an~gon~t’, supposedly i~ibi~ng the mob~~tion 
of in~a~~~ar calcium. Rarely, however, have the effects of this compound on Ca2+ movem~~ been mea- 
sured. We report here that TMB-8 is not very effective in inhibiting thrombin-induced Ca2+ influx or inter- 
nal release in human pta%elets judged from the fluorescent signal of cytoplasmic quin2. Only approx. 40% 
inhibition was seen at’500 m TMB-8. Somewhat lower concentrations blocked the secretory response to 
tbrombin and also the secretion evoked at basal [Ca”)i by phorbol ester and collrtgcn. It is suggested that 
one target for TMB-8 may be the C-kinase pathway. 
TMB-& Phorbol ester P&e/et Calcium Secretion 
1. INTRODUCTION 
8 - (N, N- Diqthylamino)octyl - 3,4,5 - trimethoxy- 
benzoate (TMB-8) was first reported as a non- 
selective inhibitor of contraction in skeletal and 
smooth inuscle, reducing the responses to a wide 
range of stimuli (see, e.g., [I]). It was reasonably 
proposed that TMB-8 acted at a late step in excita- 
tion-coritraction coupling, perhaps by ‘interfering 
with the ,availability of Ca2”. It was found that 
TMB-8 neduced 45Ca2+ ,influx and efflux in guinea 
pig ileum, and caffeine-induced release of 4sCa2+ 
from sarcoplasmic reticulum vesicles [11. Since 
then, TMB-8 has been widely described as an ‘in- 
tracellular Ca” antagonist’ and used in several 
preparations as a probe for Ca2’-mediated pro- 
cesses. Some slight justl~cation for the idea of 
Ca2+ antago~sm has come from the finding that 
the inhibitory effects of this compound are some- 
times counteracted by elevating the external Ca2+ 
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concentration. However, in most studies there has 
been no experimental test for any effect on Ca2’ 
mobilisation, whether influx or interm~I rekase. 
Indeed, it is often not clew whether investigators 
have supposed that TMB-8 is acting to prevent 
Ca2+ movements orto kkhibit he effect of Ca2+ on 
intraceklar targets. Several groups have used this 
compound to investigate activation processes in 
blood platelets 12-71 and it was even claimed that 
the inhibition by TMB-8 of secretion induced by 
thrombin or A23187 was the most direct evidence 
then available that Ca2’ is required for platelet 
secretion [2]. 
However, TMB-8 has been shown to have several 
effects in platelets, not necessarily or even easily 
attributable to Ca2’ antagonism, which is perhaps 
not s~rising in view of the very high concentra- 
tions of the compound often needed, e.g., SO- 
1000,~M. For example, TMB-8 interferes with the 
formation of thromboxane [3,7] by apparently in- 
hibiting cyclooxygenase [4]. At concentrations that 
inhibit secretion, TMB-8 causes discoid platelets to 
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become spherical, and also causes a leak of sero- 
tonin [4]. 
The introduction of the fluorescent Ca*+ indi- 
cator quin2, which can be trapped in the cytoplasm 
of intact cells [8], has allowed more direct testing 
of the effects of TMB-8 on Ca*+ mobilisation. 
Authors in [9] report that 50pM TMB-8 does in- 
deed inhibit increases in quin2 fluorescence voked 
in clutured human fibroblasts by growth factors 
and mellitin. The effects of external Ca*+ were not 
examined so it is unclear if the effect was on Ca*+ 
influx or internal release. Nor was it reported 
whether Ca*+ ionophore could bypass the suppres- 
sion of the quin2 signal. We report here the effects 
of TMB-8 in quinZloaded human platelets which 
indicate only a weak inhibitory effect on Ca*+ 
movements, but a more effective inhibition of 
secretion including that evoked by TPA (12-0- 
tetradecanoylphorbol-13-acetate), a direct activator 
of protein kinase-C [IO] that does not cause or re- 
quire any change in cytoplasmic-free calcium, 
[Ca*+]i, measurable by quin2 fluorescence [111. 
2. EXPERIMENTAL 
Human platelets were isolated from freshly 
drawn blood and loaded with approx. 1 mM quin2 
as in [l 11. The cells were resuspended in a physio- 
logical saline containing: 145 mM NaCl, 5 mM 
KCl, 1 mM MgS04,lO mM Hepes, 10 mM dextrose 
(pH 7.4) at 37’C. All preparations were preincu- 
bated in 1OOpM aspirin to eliminate the formation 
of thromboxane and avoid any effects of TMB-8 
on this pathway. Measurement of quin2 fluores- 
cence and calibration of the signal was done in a 
cuvette thermostatted to 37’C in a Perkin Elmer 
MPF44A spectrophotometer, and secretion from 
amine storage granules was measured from the 
luminescence of a luciferase preparation (Chrono- 
lume reagent) in a Chronologue lumiaggrometer, 
as in [l 11. Human thrombin (CaIbiochem) was 
added from a stock solution of 100 units/ml in 
Ca*+-free buffer. TPA (Sigma) was added from 
20pM stock dissolved in dimethylsulphoxide. Sero- 
tonin (5-hydroxytryptamine, Sigma) and cypro- 
heptadine (Sigma) were added from 1OmM or 
100 mM stocks, respectively, in physiological 
saline. Collagen (Hormon-Chemie) was added 
from a 1 mg/ml stock solution. TMB-8 was added 
from a methanol stock solution of sufficient 
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strength so that the methanol concentrations did 
not exceed 0.2%. Higher concentrations of TMB-8 
produced a small fluorescence artefact which was 
subtracted from the records. 
3. RESULTS AND DISCUSSION 
Fig.1 shows typical records of the effects of 
500,uM TMB-8 on the response to thrombin. In the 
presence or absence of external Ca*+ the secretion 
was substantially reduced. Aggregation was also 
blocked (not shown); this concentration of TMB-8 
itself produced the optical signals associated with 
shape-change. The increase in [Ca*+]i reported by 
quin2 fluorescence was much less inhibited than 
the secretion both in the presence and absence of 
external Ca*+, suggesting that neither Ca*’ influx 
nor the internal release of Ca*’ was much affected 
by TMB-8. Fig.2 shows the collected results of ex- 
periments of this type for a range of TMB-8 con- 
centrations confirming that secretion is more effec- 
tively inhibited than is the rise in [Ca*+]i. The 
secretion evoked by thrombin in the absence of 
Ca*’ may be somewhat more susceptible with an 
ICSO of 3OOpM TMB-8, than the secretion evoked 
in the presence of calcium, ICSO approx. 4OOpM. 
Protein kinase-C appears to play an important 
part in stimulus-secretion coupling in platelets 
[ 1 l-131. The phosphorylation of a protein of be- 
tween 40 and 47 kDa by this enzyme is correlated 
with secretion (see, e.g., [ 12,131) and direct activa- 
tion of protein kinase-C by TPA can evoke a secre- 
tory response that neither causes nor requires a rise 
in [Ca*‘]i judged from the quin2 signal [ll]. We 
have therefore tested the effect of TMB-8 on the 
secretion evoked by TPA. As shown in fig.3A, 
5OOpM TMB-8 completely suppressed the secre- 
tion. The collected data from this type of experi- 
ment is shown in fig,3B. The ICSO for TMB-8 is 
here distinctly lower, at 150pM, than that seen for 
thrombin-evoked responses. The reason for this 
difference is not known, but it may reflect a par- 
tially protective effect of elevated [Ca*+]i against 
inhibition by TMB-8. A similar effect was seen 
with the inhibitory effects of trifluoperazine and 
chlorpromazine [14]. These results suggest that 
TMB-8 blocks at some point in the C-kinase path- 
way but they do not say whether the phosphoryla- 
tion itself, or the actions of one of the phosphory- 
lated products, is blocked. The results in [I61 hint 
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Fig. 1. Effect of 5OOpM TMB-8 on thrombin-evoked rises in [Ca’+]i and secretion of ATP. (A) In the presence of 1 mM 
external Ca2’; (B) in the absence of added Ca”, and with 1 mM EGTA. 0.5 units/ml thrombin were added where indi- 
cated. ATP secretion is expressed as the percentage of the amount maximally releasable by thrombin in the presence 
of 1 mM Ca” (A) or in the absence of Ca2’ (B). 
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Fig.2. Dose-effect relation for TMB-8 on thrombin-evoked secretion and increase in quin2 fluorescence. (A) In the 
2+* presence of 1 mM Ca , ( ) B in the absence of added Ca2’ and with 1 mM EGTA. The bars show the SE of 3-5 determi- 
nations. Here, the secretion is expressed as a percentage of the amount seen in the absence of TMB-8. The quin2 signal 
was not converted to [Ca2’]i; the results are expressed as peak fluorescence after addition of thrombin, minus resting 
fluorescence (Aquin2 fluorescence) and expressed as a percentage of that seen in the absence of TMB-8. The curves were 
fitted by eye. 
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Fig.3. (A) Effect of SOO/rM TMB-8 on the secretion evoked by 2OnM TPA. (B) Dose-effect relation for TMB-8 on 
secretion evoked by 5 min exposure to 20nM TPA. Conditions as for fig.l,2. 
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that TMB-8 may act to inhibit the action of protein 
kinase-C. They found that a relatively low concen- 
tration of TMB-8 (75,uM) substantially reduced 
both the secretion of serotonin and the phosphory- 
lation of a 41-kDa protein evoked by platelet- 
activating factor. Interestingly, the phosphoryla- 
tion of the 20-kDa protein (presumably myosin 
light chain [17]) was inhibited less than that of the 
41-kDa protein. 
In conditions like those in fig.3 (i.e., quin2- 
loaded cells preincubated with aspirin) collagen 
evokes secretion while [Ca”]i remains at or near 
the basal level. We have proposed that diacylgly- 
cerol formed from the result of collagen-evoked 
phospholipid hydrolysis, may activate protein 
kinase-C and thereby initiate the secretory response 
[ 11,14,15]. This collagen-induced secretion was 
blocked by concentrations of trifluoperazine that 
blocked the response to TPA [14]. We therefore 
tested the effect of TMB-8 on the secretion evoked 
by 20,ug/ml collagen added to aspirin-treated cells 
in 1 mM Ca2+ medium. This secretion was blocked 
by 200/1M TMB-8, consistent with an action on the 
C-kinase pathway. Since platelets are very power- 
fully inhibited by agents, such as prostaglandin 12, 
that raise CAMP levels one should consider whether 
TMB-8 works in this way. The pattern of inhibi- 
tory effects argues strongly against this mechan- 
ism. Prostaglandin 12 very effectively suppresses 
the quin2 signals produced by thrombin, but only 
weakly inhibits the secretion evoked by TPA or 
collagen (in aspirin-treated cells) [ 181, the reverse 
of what one finds with TMB-8. 
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Our data add to those of others in showing that 
TMB-8 is a poor investigative tool. Relatively high 
concentrations are often needed to obtain inhibi- 
tion and the compound affects many different pro- 
cesses. According to our results it is not very effec- 
tive, at least in human platelets, in preventing Ca2+ 
movements even at concentrations that inhibit 
secretion. We see no evidence to suggest any 
specific interference with internal Ca2+ release. At 
concentrations that do partly inhibit Ca2’ move- 
ments, TMB-8 inhibits thromboxane production 
and causes leakage of serotonin and nucleotides. 
Furthermore, TMB-8 produces a change in absor- 
bance indicative of shape-change. Electron micro- 
graphs show TMB-&treated platelets to be spheri- 
cal [19]. As there is no increase in quin2 fluores- 
cence on addition of TMB-8, the ‘shape-change’ 
cannot be attributed to a rise in [Ca2+]i. One pos- 
sible explanation was that the change in shape was 
due to the leakage of serotonin. However, after de- 
sensitization with serotonin or treatment with the 
receptor blocker cyproheptadine, such that no 
shape-change could be obtained by the addition of 
serotonin, the change in absorbance still occurred 
on addition of TMB-8. 
TMB-8 was more effective in preventing respon- 
ses to TPA than in preventing calcium movements, 
suggesting that it acts to inhibit the C-kinase path- 
way. Such an action of TMB-8 on protein kinase-C 
may explain some of the observations in the litera- 
ture. For instance, it was reported that TMB-8 
could prevent TPA-induced secretion of lysozyme 
in human poiymorphs incubated in the absence of 
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external Ca2+ [20,21]. This result was interpreted 
as indicating that TPA acted to mobilise internal 
Ca*‘, TM&B being assumed to antagonise Ca2’ 
mobilisation. On the basis of the present data, and 
knowing that TPA can activate q&Z-loaded poly- 
morphs without any apparent rise in [Ca2’]i [22], 
we might now guess that the inhibitory effect of 
TMB-8 reflected interference with the protein 
kinase-C pathway rather than with Ca2+ mobilisa- 
tion. 
Two recent papers report effects of relatively 
low concentrations of TMB-8 that seem unlikely to 
rely on calcium antagonism. At only lOpM, TMB-8 
greatly enhauced the release of insulin from rat 
islets incubated with 1 mM isobutylmethylxanthine 
[23]. No measurements of Ca2+ movements were 
made, but the authors hypothesised that this effect 
reflected inhibition of Ca2* mobilisation from 
endoplasmic reticulum, the mechanism usually in- 
voked to explain inhibition of secretion. In another 
study, lSpM TMB-8 in~bit~, by 30%, the 
(H+ + K+)-ATPase of hog gastric mucosa [24f. 
This appeared to be due to interaction with the Ki 
site. Clearly, TMB-8 has different actions in dif- 
ferent preparations and one has to find out, rather 
than assume, its mode of action in particular con- 
ditions. 
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